
News|Articles|February 13, 2019
Tegsedi for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Author(s)Drew Boxler
Advertisement
Tegsedi (inotersen, Akcea™ Therapeutics)
Indications: Adult Patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Dosage: 284 mg adminstered by subcutaneous injection 1x weekly
Contraindications
- Platelet count less than 100 x 109/L (4, 5.1)
- History of acute glomerulonephritis caused by TEGSEDI
- Patients with a history of a hypersensitivity reaction to TEGSEDI
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
How Pharmacists Take Control of Medical Billing
2
Data Show Rise in GLP-1 Poison Center Calls Tied to Dosing Errors
3
Lowered Pneumococcal Vaccination Age Has Yet to Close Awareness Gap
4
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol
5






























